Studying Citicoline for Stroke Recovery Treatment

Unknown Phase 3 NCT06210646

Study Description

This study explores the use of citicoline in people who have had their first ischemic stroke, aiming to understand its effects on stroke recovery. Within 24 hours of experiencing a stroke, patients were given a daily dose of 1000 mg of citicoline over a period of 12 months. Their recovery was measured through several tests, such as the MoCA (Montreal Cognitive Assessment), NIHSS (National Institutes of Health Stroke Scale), and mRS (Modified Rankin Scale). Safety was also a concern, and potential side effects were monitored. The trial had a total of 800 participants, half received citicoline, and the other half were given a placebo, alongside standard antiplatelet medication. Regular assessments, including heart and brain imaging tests—like echocardiograms, ECGs, carotid duplex scans, and brain CT scans—helped track the recovery progress and any changes. The main goal of the study was to see if there were improvements in cognitive function after 6 months, and other assessments were planned for up to 12 months. Safety was assessed by recording any adverse effects that might be related to the treatment.

Study Details

Registry ID:
NCT06210646
Conditions:
Ischemic Stroke
Phase:
Phase 3
Target Enrollment:
800 participants
Start Date:
Healthy Volunteers:
No

Study Locations (1 site)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →